Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
Background: Bone marrow-derived early outgrowth cells (EOCs) secrete soluble factors that exert potent renoprotective effects, such that infusion of their conditioned medium recapitulates the affects of the cells themselves. Objectives: The objective of this study is to test whether the protective e...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-11-01
|
Series: | Canadian Journal of Kidney Health and Disease |
Online Access: | https://doi.org/10.1186/s40697-015-0082-5 |
id |
doaj-e422f8b699cf4b118277fc8c5d1d3dd8 |
---|---|
record_format |
Article |
spelling |
doaj-e422f8b699cf4b118277fc8c5d1d3dd82020-11-25T03:29:20ZengSAGE PublishingCanadian Journal of Kidney Health and Disease2054-35812015-11-01210.1186/s40697-015-0082-5Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled TrialDarren A. Yuen0David M. Kepecs1Yanling Zhang2Suzanne Advani3Kerri Thai4Kim A. Connelly5Richard E. Gilbert6 Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Division of Endocrinology, Department of Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Room 508, Toronto, ON M5B 1T8, CanadaBackground: Bone marrow-derived early outgrowth cells (EOCs) secrete soluble factors that exert potent renoprotective effects, such that infusion of their conditioned medium recapitulates the affects of the cells themselves. Objectives: The objective of this study is to test whether the protective effect of conditioned medium infusion wanes with time and whether tachyphylaxis occurs with repeated administration. Design: This is a placebo-controlled animal study. Setting: The study was conducted at St. Michael's Hospital, Toronto, Ontario, Canada. Subjects: Fischer 344 (F344) rats were used in this study. Measurements: The following were measured: (1) urinary protein:creatinine ratio, (2) glomerular filtration rate, (3) systolic blood pressure, (4) body weight, (5) glomerular endothelial cell density, and (6) glomerular and tubulointerstitial type IV collagen deposition. Methods: Subtotally nephrectomized F344 rats, a model of progressive chronic kidney disease, were randomized 4 weeks post-surgery to receive thrice-weekly intravenous injections of concentrated EOC-conditioned medium (EOC CM) or unconditioned medium (UCM) over 2 weeks. Three animal groups were studied, according to whether they were administered conditioned medium: once (Initial Therapy Only group), twice (Repeat Therapy group), or not at all (No Therapy group). Results: Following initial therapy, EOC CM-treated animals excreted less urinary protein, a marker of renal injury, than their UCM-treated counterparts. At 10 weeks post-subtotal nephrectomy, however, mean urinary protein excretion in conditioned medium-treated animals was fourfold greater than at the completion of the initial treatment course. At this time point, conditioned medium-treated animals were randomized to receive a second course of either conditioned medium (Repeat Therapy group) or unconditioned medium (Initial Therapy Only group). At study end (14 weeks post-subtotal nephrectomy), Repeat Therapy animals demonstrated higher glomerular filtration rate, less proteinuria, preserved renal microvasculature, and diminished fibrosis when compared with the No Therapy group. Initial Therapy Only animals exhibited an intermediate effect. Limitations: Testing the effect of EOC-conditioned medium in a single model of chronic kidney disease (CKD) has limitations. Conclusions: These findings suggest that early outgrowth cell-derived factors, while renoprotective, have a limited duration of action. Repeated administration of these factors, however, is able to extend the duration of efficacy and attenuate the progression of experimental chronic kidney disease.https://doi.org/10.1186/s40697-015-0082-5 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Darren A. Yuen David M. Kepecs Yanling Zhang Suzanne Advani Kerri Thai Kim A. Connelly Richard E. Gilbert |
spellingShingle |
Darren A. Yuen David M. Kepecs Yanling Zhang Suzanne Advani Kerri Thai Kim A. Connelly Richard E. Gilbert Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial Canadian Journal of Kidney Health and Disease |
author_facet |
Darren A. Yuen David M. Kepecs Yanling Zhang Suzanne Advani Kerri Thai Kim A. Connelly Richard E. Gilbert |
author_sort |
Darren A. Yuen |
title |
Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial |
title_short |
Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial |
title_full |
Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial |
title_fullStr |
Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial |
title_full_unstemmed |
Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial |
title_sort |
repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial |
publisher |
SAGE Publishing |
series |
Canadian Journal of Kidney Health and Disease |
issn |
2054-3581 |
publishDate |
2015-11-01 |
description |
Background: Bone marrow-derived early outgrowth cells (EOCs) secrete soluble factors that exert potent renoprotective effects, such that infusion of their conditioned medium recapitulates the affects of the cells themselves. Objectives: The objective of this study is to test whether the protective effect of conditioned medium infusion wanes with time and whether tachyphylaxis occurs with repeated administration. Design: This is a placebo-controlled animal study. Setting: The study was conducted at St. Michael's Hospital, Toronto, Ontario, Canada. Subjects: Fischer 344 (F344) rats were used in this study. Measurements: The following were measured: (1) urinary protein:creatinine ratio, (2) glomerular filtration rate, (3) systolic blood pressure, (4) body weight, (5) glomerular endothelial cell density, and (6) glomerular and tubulointerstitial type IV collagen deposition. Methods: Subtotally nephrectomized F344 rats, a model of progressive chronic kidney disease, were randomized 4 weeks post-surgery to receive thrice-weekly intravenous injections of concentrated EOC-conditioned medium (EOC CM) or unconditioned medium (UCM) over 2 weeks. Three animal groups were studied, according to whether they were administered conditioned medium: once (Initial Therapy Only group), twice (Repeat Therapy group), or not at all (No Therapy group). Results: Following initial therapy, EOC CM-treated animals excreted less urinary protein, a marker of renal injury, than their UCM-treated counterparts. At 10 weeks post-subtotal nephrectomy, however, mean urinary protein excretion in conditioned medium-treated animals was fourfold greater than at the completion of the initial treatment course. At this time point, conditioned medium-treated animals were randomized to receive a second course of either conditioned medium (Repeat Therapy group) or unconditioned medium (Initial Therapy Only group). At study end (14 weeks post-subtotal nephrectomy), Repeat Therapy animals demonstrated higher glomerular filtration rate, less proteinuria, preserved renal microvasculature, and diminished fibrosis when compared with the No Therapy group. Initial Therapy Only animals exhibited an intermediate effect. Limitations: Testing the effect of EOC-conditioned medium in a single model of chronic kidney disease (CKD) has limitations. Conclusions: These findings suggest that early outgrowth cell-derived factors, while renoprotective, have a limited duration of action. Repeated administration of these factors, however, is able to extend the duration of efficacy and attenuate the progression of experimental chronic kidney disease. |
url |
https://doi.org/10.1186/s40697-015-0082-5 |
work_keys_str_mv |
AT darrenayuen repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial AT davidmkepecs repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial AT yanlingzhang repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial AT suzanneadvani repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial AT kerrithai repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial AT kimaconnelly repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial AT richardegilbert repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial |
_version_ |
1724579894687432704 |